Cargando…
Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer
BACKGROUND: Hypoxia is a key driver of cancer progression. We evaluated the prognostic impact of (18)F-fluoromisonidazole (FMISO) prior to treatment in patients with breast cancer. METHODS: Forty-four patients with stage II/III primary breast cancer underwent positron emission tomography/computed wi...
Autores principales: | Asano, Aya, Ueda, Shigeto, Kuji, Ichiei, Yamane, Tomohiko, Takeuchi, Hideki, Hirokawa, Eiko, Sugitani, Ikuko, Shimada, Hiroko, Hasebe, Takahiro, Osaki, Akihiko, Saeki, Toshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063018/ https://www.ncbi.nlm.nih.gov/pubmed/30053906 http://dx.doi.org/10.1186/s13058-018-0970-6 |
Ejemplares similares
-
Correction to: Intracellular hypoxia measured by F-18 fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen-receptor positive breast (BRCR-D17-00693)
por: Asano, Aya, et al.
Publicado: (2018) -
In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
por: Ueda, Shigeto, et al.
Publicado: (2016) -
Optical Imaging for Monitoring Tumor Oxygenation Response after Initiation of Single-Agent Bevacizumab followed by Cytotoxic Chemotherapy in Breast Cancer Patients
por: Ueda, Shigeto, et al.
Publicado: (2014) -
Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
por: Sugitani, Ikuko, et al.
Publicado: (2017) -
Optical imaging of tumor vascularity associated with proliferation and glucose metabolism in early breast cancer: clinical application of total hemoglobin measurements in the breast
por: Ueda, Shigeto, et al.
Publicado: (2013)